RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolvesHims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.{}

Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.https://www.cnbc.com/2026/04/16/rfk-jr-peptides-hims-hers-glp-1.html